Cover Image
市場調查報告書

週邊動脈疾病 (PAD):美國的醫藥品市場預測與分析

Peripheral Artery Disease - US Drug Forecast and Market Analysis to 2024

出版商 GlobalData 商品編碼 370548
出版日期 內容資訊 英文 260 Pages
訂單完成後即時交付
價格
Back to Top
週邊動脈疾病 (PAD):美國的醫藥品市場預測與分析 Peripheral Artery Disease - US Drug Forecast and Market Analysis to 2024
出版日期: 2015年10月01日 內容資訊: 英文 260 Pages
簡介

本報告提供美國的週邊動脈疾病 (以下PAD)的治療藥臨床實驗趨勢與上市預測相關分析,PAD概要 (病因、病理、症狀、診斷方法等在) ,及目前的主要的治療方法,現在臨床實驗中/已上市的開發中產品的概要 (功效,SWOT分析等),市場規模預測 (總計11年份),主要的推動市場要素與其影響度等相關的調查評估。

第1章 目錄

第2章 簡介

  • 分析的背景情況
  • 相關報告
  • 近日出版的相關報告

第3章 疾病概要

  • 病因與病情
    • 病因
    • 病理生理學
  • 病期分類系統
  • 前兆、臨床症狀
  • 預後
  • 生活品質 (QoL)

第4章 疾病管理

  • 診斷、治療方法概要
    • 診斷
    • 治療指南代表性處方藥
  • 美國

第5章 競爭力的評估

  • 概要
  • 生活習慣的修正
    • 運動
    • 戒煙
  • 減輕風險要素的藥物
    • 脂質低墮胎藥
    • 降壓藥
    • 抗血栓藥
    • 血糖降落藥
    • 血栓溶解藥
  • PAD症狀的治療藥:領導品牌
    • Pletal / Pletaal (cilostazol)
    • Praxilene (naftidrofuryl oxalate)
    • Trental (pentoxifylline)
    • 前列腺素、類前列腺素的藥物療法
    • 其他藥物療法
  • 非藥物治療
    • 血管重組

第6章 未滿足需求、市場機會分析

第7章 開發中產品的評估

  • 概要
  • 臨床實驗的後期階段有潛力的醫藥品
  • 臨床實驗的初期階段有潛力的醫藥品

第8章 市場未來展望

  • 美國
    • 預測
    • 近幾年主要的事件
    • 市場促進、阻礙因素

第9章 附錄

目錄
Product Code: GDHC308CFR

In the 2014 base year, the global PAD market was worth approximately $543.4m, including both branded and generic drugs. By 2024, GlobalData expects that the global PAD market will experience significant expansion, with a Compound Annual Growth Rate (CAGR) of approximately 4.15%, equating to around $816.3m. The dramatic increase in the value of the overall global PAD therapeutics market will be partly attributable to the launch of several PAD drugs currently in late-stage pipeline development, which GlobalData believes have extraordinary potential. These include the novel antithrombotic pharmacological agents, Merck & Co.'s Zontivity (vorapaxar), AstraZeneca's Brilinta (ticagrelor), and Bayer and Janssen's (a subsidiary of Johnson & Johnson) Xarelto (rivaroxaban), which have the capacity to reform the antiplatelet and anticoagulatory PAD treatment landscape.

The total US sales for the PAD therapeutics market in the 2014 base year was approximately $191.4m. The statin share can chiefly be attributed to sales volume, as most statins, with the exception of Crestor, are available as inexpensive generics.

Scope

  • Overview of PAD including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in the US including product PADcription, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in the US from 2014-2024.
  • Analysis of the impact of key events as well the drivers and restraints affecting the US PAD market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for PAD.
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2014-2024 in US.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Classification and Staging Systems
  • 3.3. Symptoms and Clinical Presentation
  • 3.4. Prognosis
  • 3.5. Quality of Life

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Diagnosis
    • 4.1.2. Treatment Guidelines and Leading Prescribed Drugs
  • 4.2. US

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Lifestyle Modifications
    • 5.2.1. Exercise
    • 5.2.2. Smoking cessation
  • 5.3. Risk Factor Modification Drugs
    • 5.3.1. Lipid-Lowering Medical Therapies
    • 5.3.2. Antihypertensive Medical Therapies
    • 5.3.3. Antithrombotic Medical Therapies
    • 5.3.4. Glucose-Lowering Medical Therapies
    • 5.3.5. Thrombolytic Therapies
  • 5.4. Medical Therapies Treating the Symptoms of PAD - Major Brands
    • 5.4.1. Pletal / Pletaal (cilostazol)
    • 5.4.2. Praxilene (naftidrofuryl oxalate)
    • 5.4.3. Trental (pentoxifylline)
    • 5.4.4. Prostaglandin and Prostanoid Medical Therapies
    • 5.4.5. Other Pharmacological Therapies
  • 5.5. Non-Pharmacological Therapies
    • 5.5.1. Revascularization

6. Unmet Need and Opportunity Analysis

  • 6.1. Overview
  • 6.2. Enhanced Patient and Physician Education and Awareness of PAD, Facilitating Augmented Diagnosis and Treatment Rates
    • 6.2.1. Unmet Need
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunity
  • 6.3. A Greater Number of Trials Exclusively Involving PAD Patients Will Yield Improved Guidelines for the Management of PAD
    • 6.3.1. Unmet Need
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunity
  • 6.4. Superior Pharmacological Agents that Treat the Symptoms of Intermittent Claudication and Critical Limb Ischemia, but also Obviate Cardiovascular Events
    • 6.4.1. Unmet Need
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunity
  • 6.5. Unravelling the Convoluted Nature Behind the Etiology and Pathophysiology of Atherosclerosis, Which Will Potentially Lead to Treatments that Prevent or Reverse Plaque Formation
    • 6.5.1. Unmet Need
    • 6.5.2. Gap Analysis
    • 6.5.3. Opportunity

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising Drugs in Late-Stage Clinical Development
    • 7.2.1. Xarelto (rivaroxaban)
    • 7.2.2. Brilinta (ticagrelor)
  • 7.3. Promising Drugs in Early-Stage Clinical Development
    • 7.3.1. Therapeutic Angiogenesis

8. Market Outlook

  • 8.1. US
    • 8.1.1. Forecast
    • 8.1.2. Key Events
    • 8.1.3. Drivers and Barriers

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Diagnosed PAD Patients
    • 9.4.2. Percent Drug-Treated Patients
    • 9.4.3. Drugs Included in Each Therapeutic Class
    • 9.4.4. Launch and Patent Expiry Dates
    • 9.4.5. General Pricing Assumptions
    • 9.4.6. Individual Drug Assumptions
    • 9.4.7. Generic Erosion
    • 9.4.8. Pricing of Pipeline Agents
  • 9.5. Physicians and Specialists Included in this Study
  • 9.6. About the Authors
    • 9.6.1. Analyst
    • 9.6.2. Therapy Area Director
    • 9.6.3. Epidemiologist
    • 9.6.4. Global Head of Healthcare
    • 9.6.5. Global Director of Therapy Analysis and Epidemiology
  • 9.7. About GlobalData
  • 9.8. Disclaimer

List of Tables

  • Table 1: The Various Causes of PAD
  • Table 2: The Rutherford-Baker System and the Fontaine Classification for PAD
  • Table 3: The Various Etiologies of ALI
  • Table 4: The Symptoms of PAD
  • Table 5: Population Characteristics of Individuals who Require Regular Screening for PAD
  • Table 6: Treatment Guidelines for PAD
  • Table 7: 8MM, Most Prescribed Drugs for PAD by Class, 2015
  • Table 8: Country Profile - US
  • Table 9: Leading Drugs for PAD Treatment, 2015
  • Table 10: 8MM, Most Frequently Prescribed Lipid-lowering Medical Therapies
  • Table 11: Most Frequently Used Beta Blockers
  • Table 12: Product Profile - Beta Blockers
  • Table 13: Most Frequently Used ACE Inhibitors
  • Table 14: Product Profile - ACE Inhibitors
  • Table 15: Most Frequently Used ARBs
  • Table 16: Product Profile - ARBs
  • Table 17: Product Profile - Plavix (clopidogrel)
  • Table 18: Product Profile - Zontivity (vorapaxar)
  • Table 19: Efficacy and Bleeding Endpoints at Three Years in the TRA 2P-TIMI 50 Study
  • Table 20: Product Profile - Metformin
  • Table 21: Product Profile - Pletal (cilostazol)
  • Table 22: Safety Profile - Pletal (cilostazol)
  • Table 23: SWOT Analysis of Pletal, 2015
  • Table 24: Global Sales Forecast ($m) for Cilostazol, 2014-2024
  • Table 25: Product Profile - Praxilene (naftidrofuryl)
  • Table 26: Safety Profile - Praxilene (naftidrofuryl)
  • Table 27: SWOT Analysis of Praxilene, 2015
  • Table 28: Global Sales Forecast ($) for Naftidrofuryl, 2014-2024
  • Table 29: Product Profile - Trental (pentoxifylline)
  • Table 30: Most Frequently Recorded Side Effects for Pentoxifylline and Cilostazol.
  • Table 31: The Incidence (%) of Side Effects with Trental
  • Table 32: SWOT Analysis of Trental, 2015
  • Table 33: Global Sales Forecast ($m) for Pentoxifylline, 2014-2024
  • Table 34: Indications for Revascularization in PAD
  • Table 35: Major Unmet Needs and Opportunities in PAD
  • Table 36: Promising Drugs in Late-stage Clinical Development in the PAD Pipeline, 2015
  • Table 37: Comparison of Therapeutic Classes in Development for PAD, 2015
  • Table 38: Product Profile - Xarelto (rivaroxaban)
  • Table 39: SWOT Analysis of Xarelto, 2015
  • Table 40: 8MM, Sales Forecast ($m) for Xarelto, 2014-2024
  • Table 41: Product Profile - Brilinta (ticagrelor)
  • Table 42: Brilinta's Efficacy and Safety Endpoints as Three-Year Kaplan-Meier Estimates in the PEGASUS-TIMI 54 Study
  • Table 43: SWOT Analysis of Brilinta, 2015
  • Table 44: 8MM, Sales Forecast ($) for Brilinta, 2014-2024
  • Table 45: 8MM, Sales Forecast ($m) for PAD in the US, 2014-2024
  • Table 46: Key Events Impacting Sales for PAD in the US, 2014-2024.
  • Table 47: US PAD Market - Drivers and Barriers, 2014-2024.
  • Table 48: Abbreviations
  • Table 49: Key Launch Dates
  • Table 50: Key Patent Expiries
  • Table 51: High-Prescribing Physicians Non-KOLs Surveyed, By Country

List of Figures

  • Figure 1: Clinical Manifestations of PAD
  • Figure 2: Progression of PAD, Atherosclerotic Plaque Rupture and Thrombosis.
  • Figure 3: The Most Common Tests Used to Diagnose PAD in US Patients, 2014
  • Figure 4: Breakdown of US PAD Patients by Percentage (%) Predominantly Treated in Primary or Specialist Healthcare Settings, 2014
  • Figure 5: The Various Marketed and Pipeline Antithrombotic Medical Therapies for PAD
  • Figure 6: The Treatment Algorithm for IC Patients
  • Figure 7: The Treatment Algorithm for CLI Patients
  • Figure 8: The Treatment Algorithm for ALI Patients
  • Figure 9: Competitive Assessment of Late-Stage Pipeline Agents in PAD, 2014-2024
  • Figure 10: Sales for PAD in the US by Drug Class, 2014 and 2024
Back to Top